A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus Clopidogrel in Subjects With Acute Coronary Syndromes Who Are Receiving Clopidogrel.

Trial Profile

A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus Clopidogrel in Subjects With Acute Coronary Syndromes Who Are Receiving Clopidogrel.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Prasugrel (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Pharmacodynamics
  • Acronyms SWAP
  • Sponsors Eli Lilly
  • Most Recent Events

    • 13 Sep 2010 Results have been published in the Journal of the American College of Cardiology, according to an Eli Lilly media release.
    • 16 Mar 2010 Patient numbers amended from 142 to 139 as reported by ClinicalTrials.gov.
    • 21 Jul 2009 Actual end date (1 Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top